Safinamide in the management of patients with Parkinson's disease not stabilized on levodopa: a review of the current clinical evidence.

Ther Clin Risk Manag · 2018 · PMC6152599 · PMID 30271159

Europe PMC DOI

hedged sentences

0.0546

closest p · 1.1× alpha

0.0546

boldest claim

The sentences

did not reach statistical significanceP =0.0546so close (0.05 < p ≤ 0.1)

In patients with dyskinesia at baseline and no change in levodopa dose, patients in both safinamide groups had improvement in DRS score compared with placebo, but the safinamide 100 mg group did not reach statistical significance ( P =0.0546).

also in 111,027 other papers

borderline significantno p-value reported

Hierarchical analysis of the primary endpoint of improvement in UPDRS part III score showed significant improvement for safinamide 100 mg and borderline significant improvement for safinamide 50 mg.

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.